Ventyx deal a sign of  Sanofi’s growing interest neuro-immunology?

Sanofi has done two deals in three months that show it’s willing to extend its neuro-immunology focus beyond its comfort zone of multiple sclerosis. In both cases, it made tentative moves via equity investments in biotechs.

In its latest deal, announced Monday, Sanofi (Euronext:SAN; NASDAQ:SNY) made a $27 million equity investment in  Ventyx Biosciences Inc. (NASDAQ:VTYX), gaining right of first negotiation for VTX3232, a CNS-penetrant inhibitor of innate immune target NLRP3, which is in Phase II trials for Parkinson’s disease and obesity. Data from both studies are expected in 2025. ...